Compare NTRA & KMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTRA | KMB |
|---|---|---|
| Founded | 2003 | 1910 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Containers/Packaging |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.1B | 31.5B |
| IPO Year | 2015 | 1994 |
| Metric | NTRA | KMB |
|---|---|---|
| Price | $277.90 | $114.73 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 13 |
| Target Price | ★ $259.07 | $113.54 |
| AVG Volume (30 Days) | 1.5M | ★ 4.5M |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 5.33% |
| EPS Growth | ★ 0.65 | N/A |
| EPS | N/A | ★ 2.00 |
| Revenue | $210,939,000.00 | ★ $16,447,000,000.00 |
| Revenue This Year | $18.08 | $3.83 |
| Revenue Next Year | $19.65 | $3.61 |
| P/E Ratio | ★ N/A | $57.37 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $131.81 | $92.42 |
| 52 Week High | $279.42 | $137.46 |
| Indicator | NTRA | KMB |
|---|---|---|
| Relative Strength Index (RSI) | 78.21 | 76.11 |
| Support Level | $186.96 | $97.78 |
| Resistance Level | N/A | $124.21 |
| Average True Range (ATR) | 13.08 | 2.36 |
| MACD | 4.73 | 1.05 |
| Stochastic Oscillator | 99.56 | 97.95 |
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
With more than half of its sales from personal care and another third from consumer tissue products, Kimberly-Clark is a leading manufacturer in the tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates in the professional segment, partnering with businesses to provide workplace safety and sanitation solutions. Kimberly-Clark generates just over half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America. It is slated to add Kenvue's consumer health portfolio to its mix in the second half of calendar year 2026.